Product nameAnti-STAT1 antibody [15H3]
See all STAT1 primary antibodies
DescriptionMouse monoclonal [15H3] to STAT1
Tested applicationsSuitable for: ICC/IF, IP, WBmore details
Species reactivityReacts with: Human, Non human primates
Protein expressed in 293T cells transfected with Human STAT1 expression vector.
- A2058, HeLa and MCF7 cells; A549, 293T, Jurkat, A431, U2OS, COS7 whole cell lysates.
Storage instructionsShipped at 4°C. Store at -20°C.
Storage bufferPreservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 30% Glycerol, 69% PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab155933 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at 2 µg/mg of lysate.|
|WB||1/1000. Predicted molecular weight: 87 kDa.|
FunctionSignal transducer and activator of transcription that mediates signaling by interferons (IFNs). Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize, associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of interferon stimulated genes, which drive the cell in an antiviral state. In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine-phosphorylated. It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to drive the expression of the target genes, inducing a cellular antiviral state.
Involvement in diseaseNote=STAT1 deficiency results in impaired immune response leading to severe mycobacterial and viral diseases. In the case of complete deficiency, patients can die of viral disease.
Defects in STAT1 are a cause of mendelian susceptibility to mycobacterial disease (MSMD) [MIM:209950]; also known as familial disseminated atypical mycobacterial infection. This rare condition confers predisposition to illness caused by moderately virulent mycobacterial species, such as Bacillus Calmette-Guerin (BCG) vaccine and environmental non-tuberculous mycobacteria, and by the more virulent Mycobacterium tuberculosis. Other microorganisms rarely cause severe clinical disease in individuals with susceptibility to mycobacterial infections, with the exception of Salmonella which infects less than 50% of these individuals. The pathogenic mechanism underlying MSMD is the impairment of interferon-gamma mediated immunity whose severity determines the clinical outcome. Some patients die of overwhelming mycobacterial disease with lepromatous-like lesions in early childhood, whereas others develop, later in life, disseminated but curable infections with tuberculoid granulomas. MSMD is a genetically heterogeneous disease with autosomal recessive, autosomal dominant or X-linked inheritance.
Sequence similaritiesBelongs to the transcription factor STAT family.
Contains 1 SH2 domain.
modificationsPhosphorylated on tyrosine and serine residues in response to IFN-alpha, IFN-gamma, PDGF and EGF. Phosphorylation on Tyr-701 (lacking in beta form) by JAK promotes dimerization and subsequent translocation to the nucleus. Phosphorylation on Ser-727 by several kinases including MAPK14, ERK1/2 and CAMKII on IFN-gamma stimulation, regulates STAT1 transcriptional activity. Phosphorylation on Ser-727 promotes sumoylation though increasing interaction with PIAS. Phosphorylation on Ser-727 by PKCdelta induces apoptosis in response to DNA-damaging agents.
Sumoylated by SUMO1, SUMO2 and SUMO3. Sumoylation is enhanced by IFN-gamma-induced phosphorylation on Ser-727, and by interaction with PIAS proteins. Enhances the transactivation activity.
Cellular localizationCytoplasm. Nucleus. Translocated into the nucleus in response to IFN-gamma-induced tyrosine phosphorylation and dimerization.
- Information by UniProt
- Signal transducer and activator of transcription 1 91kD antibody
- CANDF7 antibody
- DKFZp686B04100 antibody
All lanes : Anti-STAT1 antibody [15H3] (ab155933) at 1/1000 dilution
Lane 1 : A549 whole cell lysate
Lane 2 : 293T whole cell lysate
Lane 3 : Jurkat whole cell lysate
Lane 4 : A431 whole cell lysate
Lane 5 : U2OS whole cell lysate
Lane 6 : COS7 whole cell lysate
Lane 7 : 3T3L1 whole cell lysate
Lysates/proteins at 25 µg per lane.
All lanes : Goat anti-mouse HRP conjugated antibody at 1/20000 dilution
Developed using the ECL technique.
Predicted band size: 87 kDa
SDS PAGE: 4-20% Tris-HCl polyacrylamide gel.
Immunofluorescent analysis of formaldehyde-fixed A2058 cells labeling STAT1 with ab155933 at 1/20 dilution (green, left image compared with control cells (right image) followed by a DyLight 488-conjugated secondary. Actin stained with Phalloidin (red) and nuclei stained with DAPI (blue).
Immunofluorescent analysis of formaldehyde-fixed HeLa cells labeling STAT1 with ab155933 at 1/20 dilution (green, left image compared with control cells (right image) followed by a DyLight 488-conjugated secondary. Actin stained with Phalloidin (red) and nuclei stained with DAPI (blue).
Immunofluorescent analysis of formaldehyde-fixed MCF7 cells labeling STAT1 with ab155933 at 1/20 dilution (green, left image compared with control cells (right image) followed by a DyLight 488-conjugated secondary. Actin stained with Phalloidin (red) and nuclei stained with DAPI (blue).
Immunoprecipitation analysis of STAT1 in U2OS cells.
750 µg of U2OS cell lysate immunoprecipitated with 2 µg ab155933.
All lanes: ab155933 at 1/1000 dilution.
Lane 1: U2OS whole cell lysate.
Lane 2: U2OS whole cell lysate immunopreciptated with ab155933.
Western Blot: 4-20% Tris-HCl polyacrylamide gel.
Secondary: Goat anti-mouse HRP conjugated antibody at 1/20000 dilution.
Predicted band size : 87 kDa.
ab155933 has not yet been referenced specifically in any publications.